Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04687761
Title Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors PETHEMA Foundation

acute myeloid leukemia


Cytarabine + Quizartinib + Venetoclax

Azacitidine + Quizartinib + Venetoclax

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.